At the news
? NEUTRALIMPACT 3/10 8-K filed Sep 8, 2026 at 07:39 ET
Pyxis Oncology appointed interim CEO Thomas Civik as permanent CEO and Chairman, replacing John Flavin who becomes Lead Independent Director. Board member Dr. Santhosh Palani resigned. The filing is a routine leadership transition with no material financial data, the company remains a clinical-stage biotech awaiting key MICVO data readouts in Fall 2026 and Q4 2026.
- Thomas Civik appointed permanent CEO and Chairman, effective September 4, 2026, after serving as interim CEO since February 2, 2026.
- John Flavin transitions from Chairman to Lead Independent Director and Chair of Compensation Committee.
- Dr. Santhosh Palani resigned from the Board effective September 4, 2026, citing increased time commitments; Board reduced from 8 to 7 members.
- Civik receives $710,000 annual base salary, 60% target bonus, $100,000 sign-on bonus, and a nonqualified stock option for 2,503,050 shares.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access